LaveezaBhattiMD,Ph.D

PubMed

• 16 citations
  TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir
  David L. Wyles, Michael S. Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi, Laveeza Bhatti, Amit Khatri, Jennifer R. King, Yiran B Hu, Roger Trinh, Nancy S. ...> ;The Journal of Infectious Diseases. 2017 Feb 15
• 16 citations
  The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/...
  David A. Wohl, Laveeza Bhatti, Catherine B. Small, Howard Edelstein, Henry H. Zhao, David A. Margolis, Edwin DeJesus, Winkler G. Weinberg, Lisa L. Ross, Shaefer> ;HIV Medicine. 2016 Feb 1
• 254 citations
  Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
  , , , , , , , , , , , , , , , , , , , , , , , > ;JAMA. 2015 Mar 24
• 20 citations
  Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferior...
  David A. Wohl, Laveeza Bhatti, Catherine B. Small, Howard Edelstein, Henry H. Zhao, David A. Margolis, Edwin DeJesus, Winkler G. Weinberg, Lisa L. Ross, Mark S. Shaefer> ;Plos One. 2014 May 13
• 1 citations
  Once-Daily Nevirapine XR A Brief Overview of the Safety and Efficacy of a New Formulation
  Laveeza Bhatti, Jay Gladstein> ;Journal of the International Association of Physicians in AIDS Care. 2012 Aug 27
• Join now to see all

Journal Articles

• Turquoise-! Part 1b: Ombitasvir/Paritapavir/Ritonavir and Dasabuvir with Ribavarin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir  
  Wyles D., Saag M., Viani R.M., Lalezari J., Adeyemi O., Bhatti L., Khatri A., King J.R., Hu Y.B., Trinh R., Shulman N.S., and Ruane P, JID, 1/1/2017
• Ombitasvir Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 - A Randomized Trial  
  Sulkowski M.S., Eron J.J., Wyles D., Trinh R., Lalezari J., Wang C., Slim J., Bhatti L., Gathe J., Ruane P.J., Elion R., Breedek F., Breenan R., Gary B., Khatri A., Gi..., JAMA, 1/1/2015
• Once Daily Nevirapine XR: A Brief Overview of the Safety and Efficacy of a New Formulation  
  Bhatti, L, and J. Gladstein, Journal of the International Association of Physicians in Aids Care, 1/1/2012
• Patient and Provider Characteristics Associated with the Decision of HIV Co-infected Patients to Start Hepatitis C Treatment  
  Oscilla, K.C., G.J. Wagner, J. Garnett, B. Ghosh-Dastidar, L. Bhatti, M. Witt, and M. B. Goetz, AIDS Patient Care and STDs, 1/1/2011
• Patient Characteristics Associated with HCV Treatment Adherence, Completion, and Sustained Virologic Response in HIV Co-infected Patients  
  Wagner, G, K.C. Osilla, Bhatti, L., Goetz M, and Witt M, Aids Research and Treatment, 1/1/2011
• Clinical Safety and Long-term Efficacy of Nevirapine among Women in an Urban HIV Clinic - A Case Series  
  Bhatti L, Infectious Diseases in Clinical Practice, 1/1/2011
• A Randomized Comparison of Safety and Efficacy of Nevirapine vs Atazanavir/ Ritonavir Combined with Tenofovir/ Emtricitabine in Treatment Naïve Patients  
  DeJesus, E., Mills A, Bhatti L, Conner C, and Storfer S, International Journal of Clinical Practice, 1/1/2011
• Susceptibility of HIV-1 Isolates to Tipranavir and other Antiviral Agents in Treatment-Experienced Patients: The UTILIZE Study  
  Baxter, J.D., Bhatti, L., E. Coakley, J. Bartczak, M. McDonough, R. Vinisko, and P.J. Piliero, Current HIV Research, 1/1/2010
• Treat Early or Wait and Monitor? A Qualitative Analysis of Provider HCV Treatment Decision Making in the Context of HIV Co-infection  
  Wagner, G, G. Ryan, K.C. Osilla, L. Bhatti, M. Goetz, and M. Witt, AIDS Patient Care & STDs, 1/1/2009
• Hepatitis C Patients' Self-Reported Adherence to Pegylated Interferon and Ribovin  
  Weiss, J, L. Bhatti, B. Ellin, D. Fishbein, M. Goetz, J. Jones, V. Khotiva, A. Uriela, K. Yu, A. Wagner, Alimentary Pharmacol Ther, 1/1/2008
• HCV/ HIV Co-infection in Women: A Paucity of Information (Mujeres con VIH y VHC: Una Penuria de Informacion) Aids Project Los Angeles  
  Bhatti L, Impacto. Spring, 1/1/2007
• The Safety and Efficacy of Dose-sparing Intradermal Administration of Influenza Vaccine in Human Immunodeficiency Virus-positive Patients  
  Khanlou H., Sanchez S., Babaie M., Chien C., Hamwi G., Ricaurte J.C., Stein T., Bhatti L., Denouden P., and Farthing C., Archives of Internal Medicine, 1/1/2006
• Farthing Interaction Between Atazanavir and Fosamprenavir in the Treatment of HIV-Infected Patients  
  Khanlou, H., L. Bhatti, C., Journal of Acquired Immune Deficiency Syndromes, 1/1/2006
• Pilot Study of Directly Observed Therapy in Highly Nonadherent HIV-Infected Patients in an Urban Community-based Institution  
  Khanlou, H., V. Kandoula, V. Yeh, T. Stein, S. Sanchez, J. C. Ricaurte, L. Bhatti, and C. Farthing, Journal of Acquired Immune Deficiency Syndrome, 1/1/2003
• Disseminated Echinococcus presenting as Chronic Headache in a Fifty-five Year Old Middle-eastern Woman: Case Report and Review  
  Bhatti L, Infectious Disease in Clinical Practice, 1/1/1999
• Disseminated Echinococcus presenting as Chronic Headache in a Fifty-five Year Old Middle-eastern Woman: Case Report and Review  
  Chaudhry, S., B. Kubak, N. Martin, L. Bhatti, M. Alexander, and J. O'Connell, Infectious Diseases in Clinical Practice, 1/1/1999
• Transcriptional Regulation by Retinoic Acid of Interleukin-2 Alpha Receptor on a Human B Cell Line  
  Bhatti, L., and N. Sidell, Immunology, 1/1/1994
• Upregulation by Retinoic Acid of Interleukin-2 Receptor mRNA in Human T Lymphocytes  
  Sidell, N., B. Chang and L. Bhatti, Cellular Immunology, 1/1/1993
• Inhibition of B Cell Proliferation by Antisense DNA to both a and b forms of Fc (inverted A) R II  
  Bhatti, L., K. Behle and R. H. Stevens, Cellular Immunology, 1/1/1992
• Transcriptional Regulation by Retinoic Acid of Interleukin-2 Alpha Receptor on a Human B Cell Line  
  Bhatti, L. and N. Sidell, Faseb Journal, 1/1/1992
• Soluble CD-23 containing B Cell Supernatants Induce IgE from Peripheral Blood B-lymphocytes and Co-stimulate with Interleukin-4 in Induction of IgE  
  Saxon, A., Z. Ke, L. Bhatti and R. H. Stevens, Journal of Allergy and Clinical Immunology, 1/1/1990
• T4+ T Helper Cell Function in vivo: Differential Requirement for Induction of Antiviral Cytotoxic T-cell and Antibody Responses  
  Ahmed, R., L. D. Butler, and L. Bhatti, Journal of Virology, 1/1/1988
• Join now to see all

Abstracts/Posters

• Pilot Study Evaluating the Safety and Efficacy of Dose Sparing Intradermal Administration of Influenza Vaccine in HIV-Positive Patients.
  Khanlou,H., S. Sanchez, M. Babaie, C. Chien, J.C. Ricaurte, T. Stein, L. Bhatti, P. Denouden, A. Voskanian and C. Farthing, CROI, 1/1/2006

Lectures

• Efficacy and Safety of Switching from Boosted-protease Inhibitor Plus Emtricitabine/Tenofovir Disoproxil Fumarate Regimens to the Single-tablet Regimen of Darunavir/Co... 
  Paris, France - 1/23/2017
• TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r+Dasabuvir+RBV for HCV/HIV Coinfection. 
  Boston, MA, 2016; Mendoza, Argentina, 2016 - 1/22/2016
• Improvement in Liver Fibrosis, Necroinflammatory Scores and Liver Function Tests in Achieving SVR with DAA Treatment in HIV/HEP-C Co-infected Patients in a Ryan White ... 
  Moran, WY - 1/15/2016
• Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected with HIV-1 in the TURQUOISE-I Trial. 
  Seattle, WA - 1/23/2015
• High SVR Rates in HCV/HIV-1 CO-infected Patients Regardless of Baseline Characteristics. 
  Mexico City, Mexico - 1/16/2015
• Comparative Results of Fibroscan and FibroSure in HIV/HCV Co-infected Pretreatment Patients in a Ryan White Funded Clinic in Los Angeles. 
  Wailea, HI - 1/6/2015
• TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin. 
  Boston, MA - 1/7/2014
• Once-Daily Oral GSK1265744 (744) as Part of Combination Therapy in Antiretroviral-Naive Adults: 24-Week Safety and Efficacy Results From the LATTE Study (LAI116482). 
  Brussels, Belgium - 1/16/2013
• Virologic Responses to Telaprevir/ PEG/ RBV Therapy in HCV/HIV Co-infected Patients at a Public Clinic in Los Angeles, CA. 
  Big Island, HI - 1/8/2013
• Simplification to Abacavir/Lamivudine + Atazanavir from Tenofovir/ Emtricitiabine + Atazanavir/ Ritonavir Maintains Viral Suppression and Improves Bone Biomarkers. 
  San Francisco, CA - 1/9/2012
• IL-28B Polymorphism Does Not Predict Outcome to Hepatitis C Treatment in HCV/HIV Co-infected Patients. 
  Rome, Italy - 1/17/2011
• Transitioning from Guidelines to Clinical Practice: PMTCT at Labor & Delivery Wards in Guyana. 
  Rome, Italy - 1/17/2011
• Bhatti, L., S. Shah, and H. Khanlou 
  Cabo San Lucas, Mexico - 1/7/2010
• Nevirapine (NVP) vs. Boosted Atazanavir (ATV/r) in Antiretroviral Naïve Patients: The NEWART Trial, 48-Week Results. 
  Glasgow, United Kingdom - 1/7/2010
• Response to Treatment of Hepatitis C in HCV/HIV Co-infected Patients Is Not Influenced by Either Abacavir or Tenofovir with Weight-based Ribavirin. 
  Glasgow, United Kingdom - 1/7/2010
• Long-Term Hepatic Safety of Lopinavir/Ritonavir Containing Regimens in the Treatment of HIV-HCV Co-Infected Patients. 
  1/1/2006
• Join now to see all